Holen Sie sich die Stockscreener-App
167.55
1.71%
2.82
Handel nachbörslich:
168.25
0.70
+0.42%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$164.73
Offen:
$164.72
24-Stunden-Volumen:
2.62M
Relative Volume:
1.56
Marktkapitalisierung:
$24.57B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
16.03
EPS:
10.453
Netto-Cashflow:
$1.85B
1W Leistung:
+7.74%
1M Leistung:
+15.31%
6M Leistung:
+39.20%
1J Leistung:
+1.61%
1-Tages-Spanne:
$163.00
$169.00
1-Wochen-Bereich:
$153.77
$169.00
52-Wochen-Spanne:
$110.03
$169.00
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
167.55 | 24.17B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,025.28 | 915.49B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
195.93 | 470.41B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
232.36 | 410.55B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.26 | 253.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
92.92 | 230.65B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
STATE STREET CORP Reduces Stake in Biogen Inc: A Detailed Analys - GuruFocus
Analyzing Biogen Inc. with multi timeframe chartsJuly 2025 Retail & Verified Momentum Watchlists - newser.com
Biogen Completes Acquisition of Alcyone Therapeutics - MarketScreener
Biogen completes acquisition of Alcyone Therapeutics By Investing.com - Investing.com India
Fund Update: 282,084 BIOGEN (BIIB) shares added to Zurcher Kantonalbank (Zurich Cantonalbank) portfolio - Quiver Quantitative
Biogen completes acquisition of Alcyone Therapeutics - MarketScreener
Discipline and Rules-Based Execution in BIIB Response - news.stocktradersdaily.com
Biogen stock hits 52-week high at 167.87 USD By Investing.com - Investing.com Canada
Biogen stock hits 52-week high at 167.87 USD - Investing.com India
How to escape a deep drawdown in Biogen Inc.Trade Exit Summary & Stepwise Trade Signal Implementation - newser.com
Biogen (BIIB) Gains UK Approval for LEQEMBI Maintenance Dosing - GuruFocus
'LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom - The Manila Times
Eisai and Biogen's LEQEMBI® Receives Approval for Once Every Four Weeks IV Maintenance Dosing in the UK - Quiver Quantitative
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the - GlobeNewswire
Biogen at TD Cowen Summit: Strategic Focus on I&I and Kidney Innovation - Investing.com India
Biogen (BIIB) Valuation in Focus Following Q3 2025 Results and Key Medical Conference Updates - simplywall.st
Biogen Inc: Time to Ride the Surge? - timothysykes.com
What the Options Market Tells Us About Biogen - Benzinga
Biogen Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month - Yahoo Finance
Chart based exit strategy for Biogen Inc.July 2025 Selloffs & Safe Capital Growth Tips - newser.com
Biogen’s Alzheimer’s Bet: Can the EVOKE Trial Redefine the Future of Neurology? - Smartkarma
Key metrics from Biogen Inc.’s quarterly dataJuly 2025 Snapshot & Advanced Swing Trade Entry Plans - newser.com
Why Biogen Inc. (IDP) stock benefits from AI revolutionTrade Exit Summary & Safe Entry Zone Identification - newser.com
Institutional scanner results for Biogen Inc.Earnings Risk Report & AI Driven Stock Reports - newser.com
Biogen Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains - 富途牛牛
Will Biogen Inc. (IDP) stock benefit from commodity supercycleWeekly Stock Analysis & Community Verified Trade Signals - newser.com
Why Biogen Inc. (IDP) stock stays on top picksDay Trade & Real-Time Market Trend Scan - newser.com
Should you wait for a breakout in Biogen Inc.July 2025 Fed Impact & High Accuracy Investment Signals - newser.com
How Biogen’s (BIIB) Strong Q3 Earnings and New Product Growth Could Shape Its Investment Outlook - simplywall.st
Alzheimer’s drug uptake hits its stride after a sluggish start - PharmaVoice
Why Biogen Inc. stock is considered a top pickWeekly Investment Recap & Community Supported Trade Ideas - newser.com
Biogen Inc.’s volatility index tracking explainedAnalyst Upgrade & Weekly Return Optimization Plans - newser.com
Dementia Market Is Booming Worldwide 2025-2032 | Eli Lilly, Biogen, Novartis, and Roche - openPR.com
How a Strong Q3 and Increased R&D Spending at Biogen (BIIB) Has Changed Its Investment Story - Sahm
Is Biogen Worth a Fresh Look After Major Drug Approvals in 2025? - simplywall.st
When is the best time to exit Biogen Inc.2025 Major Catalysts & Technical Entry and Exit Tips - newser.com
Should Biogen’s (BIIB) Surging New Drug Sales Reshape Investors’ Expectations for Future Growth? - Yahoo Finance
Biogen Shares Recover Slightly Amid Clinical Trial Partnerships — Is the Stock Trading Below Fair Value? - Yahoo Finance
Stifel Upgrades Biogen (BIIB) - Nasdaq
Biogen Shares Rise After Stifel Upgrade - MarketScreener
Biogen (BIIB) Valuation in Focus After Q3 Earnings Growth and Share Buyback Update - simplywall.st
December 26th Options Now Available For Biogen (BIIB) - Nasdaq
Historical volatility pattern of Biogen Inc. visualized2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More - MSN
Stifel Upgrades Biogen (BIIB) to 'Buy', Raises Price Target to $202 | BIIB Stock News - GuruFocus
Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift - Yahoo! Finance UK
Here Are Thursday's Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More - 24/7 Wall St.
Will Biogen Inc. stock benefit from upcoming earnings reportsRisk Management & Technical Pattern Based Signals - Fundação Cultural do Pará
Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift By Investing.com - Investing.com Canada
Using portfolio simulators with Biogen Inc. included2025 Institutional Moves & Short-Term Trading Alerts - newser.com
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biogen Inc-Aktie (BIIB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Godbout Sean | Chief Accounting Officer |
Oct 02 '25 |
Option Exercise |
0.00 |
26 |
0 |
503 |
| Singhal Priya | Head of Development |
Aug 29 '25 |
Option Exercise |
0.00 |
1,669 |
0 |
7,096 |
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
0.38%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):